Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.

Molecular cancer therapeutics - 1 Sept 2015

Yarar Defne, Lahdenranta Johanna, Kubasek William, Nielsen Ulrik B, MacBeath Gavin

Abstract excerpt

PI3K is frequently mutated in cancer and plays an important role in cell growth and survival. Heregulin (HRG)-mediated autocrine or paracrine signaling through the receptor tyrosine kinase ErbB3 potently activates the PI3K/AKT pathway and has been shown to mediate resistance to a wide variety of anticancer agents. Although PI3K functions downstream of HRG-ErbB3, it is unknown whether activating mutations in PI3K...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Neoplasms

Share to Neuregulin-1

Share to Phosphatidylinositol 3-Kinases

Share to Receptor, ErbB-3

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 26116360
DOI: 10.1158/1535-7163.MCT-15-0075

Genes

HRG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.PMID 26116360Read ↗

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.Semantic proximity Read ↗

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.Semantic proximity Read ↗

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid TumorsSemantic proximity Read ↗

What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase PathwaySemantic proximity Read ↗

Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.Semantic proximity Read ↗

ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.Semantic proximity Read ↗

Targeting HER proteins in cancer therapy and the role of the non-target HER3Semantic proximity Read ↗

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell linesSemantic proximity Read ↗

A global microRNA screen identifies regulators of the ErbB receptor signaling networkSemantic proximity Read ↗

HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.Semantic proximity Read ↗

Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.Semantic proximity Read ↗

Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.